학술논문
BAP1 Loss, Nuclear Grading, and Nonepithelioid Features in the Diagnosis of Mesothelioma in Italy: Nevermore without the Pathology Report.
Document Type
Academic Journal
Author
Rossi G; Pathology Unit, Services Area, Fondazione Poliambulanza Hospital Institute, Via Bissolati 57, 25124 Brescia, Italy.; Fondazione FONICAP, Via Locchi, 26, 37124 Verona, Italy.; Righi L; Department of Oncology, University of Turin, San Luigi Hospital, 10043 Orbassano, Italy.; Barbisan F; Pathological Anatomy Institute, Polytechnic University of Marche Region, 60126 Ancona, Italy.; Tiseo M; Department of Medicine and Surgery, University of Parma and Medical Oncology Unit, University Hospital of Parma, 43126 Parma, Italy.; Spagnolo P; Respiratory Disease Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, 35128 Padova, Italy.; Grosso F; Mesothelioma Unit, AO SS. Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, Italy.; Pisapia P; Department of Public Health, Federico II University of Naples, Via Sergio Pansini 5, 80131 Naples, Italy.; Malapelle U; Department of Public Health, Federico II University of Naples, Via Sergio Pansini 5, 80131 Naples, Italy.; Sculco M; Department of Health Sciences, Università del Piemonte Orientale, 28100 Novara, Italy.; Dianzani I; Department of Health Sciences, Università del Piemonte Orientale, 28100 Novara, Italy.; Abate-Daga L; TU.TO.R. Tumori Toracici Rari, Patient Advocacy, 20123 Milan, Italy.; Davolio MC; Legal Medicine and Risk Management Department, Azienda Unità Sanitaria Locale di Modena, Strada Martiniana, 21, 41126 Modena, Italy.; Ceresoli GL; Medical Oncology, Humanitas Gavazzeni Clinic, 24125 Bergamo, Italy.; Galetta D; Medical Thoracic Oncology Unit, IRCCS Istituto Tumori 'Giovanni Paolo II', 70124 Bari, Italy.; Pasello G; Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.; Department of Surgery, Oncology and Gastroenterology, University of Padua, 35128 Padua, Italy.; Novello S; Department of Oncology, University of Turin, San Luigi Hospital, 10043 Orbassano, Italy.; Bironzo P; Department of Oncology, University of Turin, San Luigi Hospital, 10043 Orbassano, Italy.
Source
Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101602269 Publication Model: Electronic Cited Medium: Print ISSN: 2075-4426 (Print) Linking ISSN: 20754426 NLM ISO Abbreviation: J Pers Med Subsets: PubMed not MEDLINE
Subject
Language
English
ISSN
2075-4426
Abstract
The pathologic diagnosis of pleural mesothelioma is generally based on international guidelines, but no compulsory points based on different drugs approvals in different European countries are required to be reported. According to the last (2021) edition of the World Health Organization classification of pleural tumors, the nuclear grade of epithelioid-type mesothelioma should be always inserted in the pathologic report, while the presence of BRCA-associated protein-1 (BAP1) (clone C4) loss and a statement on the presence of the sarcomatoid/nonepithelioid component are fundamental for both a screening of patients with suspected BAP1 tumor predisposition syndrome and the eligibility to perform first-line immunotherapy at least in some countries. Several Italian experts on pleural mesothelioma who are deeply involved in national scientific societies or dedicated working groups supported by patient associations agreed that the pathology report of mesothelioma of the pleura should always include the nuclear grade in the epithelioid histology, which is an overt statement on the presence of sarcomatoid components (at least 1%, in agreement with the last classification of pleural mesothelioma) and the presence of BAP1 loss (BAP1-deficient mesothelioma) or not (BAP1-retained mesothelioma) in order to screen patients possibly harboring BAP1 tumor predisposition syndrome. This review aims to summarize the most recent data on these three important elements to provide evidence regarding the possible precision needs for mesothelioma.